Tuesday, July 1, 2025 7/1/2025

Virally-induced tumorigenesis controlled by the microbiota

Award Number: R01CA232882
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2019
PERIOD OF PERFORMANCE END DATE: 02/28/2030

Group Awards By:

View Award Description

Virally-induced tumorigenesis controlled by the microbiota - Abstract All multicellular organisms are colonized with a diverse and complex population of microbes including bacteria, viruses, fungi, archaea, and protozoans, collectively called the microbiota. Microbiota play an integral role in modulating host health by providing necessary nutrients, by protecting against incoming bacterial pathogens and by supporting the development and maturation of the immune system. Microbiota could also impact cancer development at various stages by modulating cell proliferation and death, altering the function of the immune system, and influencing metabolism of various compounds. Murine Leukemia Virus (MuLV) is highly proficient in causing leukemia in mice from susceptible strains. Using MuLV, we found that some gut commensal bacteria promoted the development of leukemia induced by this retrovirus. The promotion of leukemia development by commensal bacteria was due to suppression of the adaptive immune response through upregulation of several negative regulators of immunity. These negative regulators included serine (or cysteine) peptidase inhibitor, clade B, member 9b (Serpinb9b) and Ring finger protein 128 (Rnf128). Serpinb9b is known to counteract killing by cytotoxic granzymes and was upregulated in leukemic cells. Rnf128 known for induction of unresponsiveness of T cells was induced uniquely in CD4 T cells. Genetic ablation of these genes conferred resistance to virally-induced leukemia even in the presence of a complex microbiota. Upregulation of Serpinb9b was mediated via the RIPK2 pathway (downstream of NOD1 and NOD2 receptors which detect various forms of peptidoglycan). As Serpinb9b and Rnf128 are associated with a poor prognosis of some spontaneous human cancers, the mechanism of bacterially-induced immunosuppression during tumor development may apply to human tumors of virally and non-viral origin. The current proposal aims at defining the precise mechanism(s) by which microbially-induced negative immune regulators contribute to leukemia progression. Specifically, we will identify the innate immune receptors bacterial products signal through to induce negative immune regulators and determine the adoptive mechanism which controls leukemia development in the absence of bacteria.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $534,676 )
2025	2025	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Biology Research	001	6	3/10/2025	COMPETING CONTINUATION	$534,676
2025	2023	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Cause and Prevention Research	000	5	3/10/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $534,676

Issue Date FY: 2023 ( Subtotal = $467,351 )
2023	2023	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Cause and Prevention Research	000	5	6/13/2023	NON-COMPETING CONTINUATION	$467,351
														Subtotal = $467,351

Issue Date FY: 2022 ( Subtotal = $467,351 )
2022	2022	UNIVERSITY OF CHICAGO	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Cause and Prevention Research	000	4	7/18/2022	NON-COMPETING CONTINUATION	$467,351
														Subtotal = $467,351

Issue Date FY: 2021 ( Subtotal = $476,888 )
2021	2021	UNIVERSITY OF CHICAGO, THE	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Cause and Prevention Research	000	3	6/9/2021	NON-COMPETING CONTINUATION	$476,888
														Subtotal = $476,888

Issue Date FY: 2020 ( Subtotal = $476,888 )
2020	2020	UNIVERSITY OF CHICAGO, THE	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Cause and Prevention Research	000	2	6/11/2020	NON-COMPETING CONTINUATION	$476,888
														Subtotal = $476,888

Issue Date FY: 2019 ( Subtotal = $492,388 )
2019	2019	UNIVERSITY OF CHICAGO, THE	5801 S ELLIS AVE	CHICAGO	IL	60637	COOK	USA	Cancer Cause and Prevention Research	000	1	2/25/2019	NEW	$492,388
														Subtotal = $492,388

Grand Total All Awards = $2,915,542

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Virally-induced tumorigenesis controlled by the microbiota

Award Number: R01CA232882

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2019

PERIOD OF PERFORMANCE END DATE: 02/28/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer